Haemonetics Corporation Earnings Recaps
Q4 2026
May 11, 2026
Shares fell 3.9% as investors reacted negatively to persistent weakness and declines in the interventional technologies segment, overshadowing solid growth elsewhere and a cautious stance on near-term growth drivers.
Key takeaways
- Total revenue was $346 million in Q4, up 5% reported and 9% organic ex-CSL; full fiscal year revenue totaled $1.3 billion.
- Interventional technologies revenue fell 10% in Q4 and 9% for the year, with vascular closure down 8%, driven by share losses and ongoing procedural headwinds.
- Blood management technologies posted strong growth, with blood management up 21% in the quarter and 14% for the year, led by TEG 6s adoption and European expansion.
- Plasma franchise grew 3% reported and 13% organic ex-CSL in Q4, supported by strong U.S. and European share gains and new product launches like Persona PLUS.
- Fiscal 2027 guidance expects 4–7% reported revenue growth, excluding contribution from PerQseal Elite still under FDA review, highlighting cautious near-term expectations.
Q3 2026
Feb 5, 2026
Haemonetics Corporation reported strong third-quarter results for Fiscal Year 2026, raising full-year guidance for revenue, earnings, and free cash flow, driven by robust growth in Blood Management Technologies and Plasma.
Key takeaways
- Third-quarter revenue reached $339 million, with organic growth ex CSL of 8% in the quarter and 10% year-to-date.
- Adjusted earnings per share increased by 10% to $1.31, reflecting durable earnings quality.
- Blood Management Technologies grew 8% in the quarter, bolstered by TEG 6s disposable sales and hemostasis management.
- Plasma segment performance saw a dramatic organic growth of 20%, supported by strong demand and share gains, prompting an uptick in full-year revenue guidance.
- Hospital business organic growth guidance adjusted to approximately 4%, now anticipated at the low end of the previous range.